MCID: ANX010
MIFTS: 72

Anxiety

Categories: Genetic diseases, Mental diseases, Neuronal diseases

Aliases & Classifications for Anxiety

MalaCards integrated aliases for Anxiety:

Name: Anxiety 57 12 29 6 43 40 73
Anxiety Disorders 55 44 73
Anxiety Disorder 12 15
Anxiety State 12 73
Anxiety Neurosis 73

Classifications:



External Ids:

OMIM 57 607834
Disease Ontology 12 DOID:2030
ICD10 33 F41.9 F41.8
ICD9CM 35 300.09
MeSH 44 D001008
NCIt 50 C2878
MedGen 42 C0003467

Summaries for Anxiety

OMIM : 57 Human personality is shaped by genetic and environmental factors, and evidence suggests that the genetic component is highly complex, polygenic, and epistatic. Genetic factors are thought to contribute to 40 to 60% of trait variance. Molecular genetics has tried to identify specific genes for quantitative traits, called quantitative trait loci (QTLs). The QTL concept suggests that complex personality traits or dimensions are not attributable to single genes, but to multiple interacting genes (Reif and Lesch, 2003). Fullerton et al. (2003) stated that psychologists were in agreement that the wide variation in human personalities can be explained by a small number of personality factors, including neuroticism (a measure of emotional stability), which manifests at one extreme as anxiety, depression, moodiness, low self-esteem, and diffidence. They cited a number of studies that had described a relationship between high scores on measures of neuroticism and major depressive disorder. They also noted that theoretical studies had suggested that large samples of randomly ascertained sibs could be used to ascertain phenotypically extreme individuals and thereby increase power to detect genetic linkage in complex traits. See also panic disorder (PAND1; 167870), which is a subtype of anxiety disorder. (607834)

MalaCards based summary : Anxiety, also known as anxiety disorders, is related to social phobia and generalized anxiety disorder, and has symptoms including nervousness, agitation and feeling tense. An important gene associated with Anxiety is SLC6A4 (Solute Carrier Family 6 Member 4), and among its related pathways/superpathways are Peptide ligand-binding receptors and G-Beta Gamma Signaling. The drugs Alprazolam and Valproic Acid have been mentioned in the context of this disorder. Affiliated tissues include brain, breast and testes, and related phenotypes are behavior/neurological and homeostasis/metabolism

MedlinePlus : 43 Fear and anxiety are part of life. You may feel anxious before you take a test or walk down a dark street. This kind of anxiety is useful - it can make you more alert or careful. It usually ends soon after you are out of the situation that caused it. But for millions of people in the United States, the anxiety does not go away, and gets worse over time. They may have chest pains or nightmares. They may even be afraid to leave home. These people have anxiety disorders. Types include Panic disorder Obsessive-compulsive disorder Post-traumatic stress disorder Phobias Generalized anxiety disorder Treatment can involve medicines, therapy or both. NIH: National Institute of Mental Health

Disease Ontology : 12 A cognitive disorder that involves an excessive, irrational dread of everyday situations.

Wikipedia : 76 Anxiety is an emotion characterized by an unpleasant state of inner turmoil, often accompanied by... more...

Related Diseases for Anxiety

Diseases related to Anxiety via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 532)
# Related Disease Score Top Affiliating Genes
1 social phobia 33.9 HTR1A MAOA SLC6A4
2 generalized anxiety disorder 33.7 BDNF CRHR1 HTR1A HTR2A MAOA SLC6A4
3 phobic disorder 33.2 COMT HTR1A MAOA PTK7 SLC6A4
4 phobia, specific 32.9 COMT MAOA
5 alcohol abuse 32.6 BDNF CNR1 SLC6A4
6 agoraphobia 32.6 CCKBR HTR1A MAOA PTK7 SLC6A4
7 fibromyalgia 32.4 COMT CRH HTR2A SLC6A4
8 irritable bowel syndrome 32.2 CRH CRHR1 SLC6A4 TPH1
9 bulimia nervosa 32.0 BDNF COMT HTR2A MAOA SLC6A4
10 eating disorder 32.0 BDNF CNR1 COMT CRH HTR2C SLC6A4
11 postpartum depression 31.9 BDNF COMT CRH HTR1A MAOA SLC6A4
12 alexithymia 31.5 COMT HTR1A SLC6A4
13 post-traumatic stress disorder 31.2 BDNF CNR1 COMT CRH HTR2A MAOA
14 conduct disorder 30.9 COMT MAOA SLC6A4 TPH1
15 chronic pain 30.8 CNR1 COMT
16 premature ejaculation 30.8 COMT HTR1A HTR2C SLC6A4
17 antisocial personality disorder 30.8 COMT MAOA SLC6A4
18 obsessive-compulsive disorder 30.7 BDNF COMT CYP2D6 HTR1A HTR2A HTR2C
19 dysthymic disorder 30.7 HTR2A MAOA SLC6A4
20 parkinson disease, late-onset 30.7 BDNF CNR1 COMT CYP2D6 HTR1A HTR2A
21 anorexia nervosa 30.7 BDNF COMT CRH HTR2A SLC6A4
22 tobacco addiction 30.6 COMT HTR2A MAOA TPH1
23 oppositional defiant disorder 30.6 COMT MAOA SLC6A4 TPH2
24 drug dependence 30.5 BDNF CNR1 CRH SLC6A4
25 pathological gambling 30.5 HTR2A MAOA SLC6A4
26 panic disorder 30.4 BDNF CCKBR COMT CRH CRHR1 HTR1A
27 substance abuse 30.4 BDNF COMT CYP2D6 MAOA SLC6A4
28 schizoaffective disorder 30.4 BDNF COMT HTR2A SLC6A4
29 bipolar disorder 30.2 BDNF COMT CRH HTR1A HTR2A HTR2C
30 autism 30.2 BDNF COMT HTR1A HTR2A MAOA SLC6A4
31 bipolar i disorder 30.2 BDNF COMT HTR1A HTR2A HTR2C SLC6A4
32 endogenous depression 30.1 BDNF CRH MAOA SLC6A4
33 schizophrenia 30.1 BDNF CNR1 COMT CYP2D6 HTR1A HTR2A
34 substance dependence 30.0 BDNF CNR1 CYP2D6 MAOA SLC6A4
35 cannabis abuse 30.0 BDNF CNR1
36 migraine with or without aura 1 30.0 CNR1 COMT CYP2D6 HTR1A HTR2A HTR2C
37 depression 29.9 BDNF CRH CRHR1 HTR1A HTR2A HTR2C
38 narcolepsy 29.8 COMT HTR2A NPS TPH1
39 personality disorder 29.7 BDNF COMT HTR1A HTR2A HTR2C MAOA
40 early-onset schizophrenia 29.6 BDNF COMT HTR2A MAOA SLC6A4
41 paranoid schizophrenia 29.6 BDNF COMT HTR2A MAOA SLC6A4 TPH2
42 chronic fatigue syndrome 29.4 COMT CRH HTR1A MAOA NR3C1 SLC6A4
43 attention deficit-hyperactivity disorder 29.0 BDNF COMT CYP2D6 HTR1A HTR2A HTR2C
44 psychotic disorder 28.9 BDNF CNR1 COMT CYP2D6 HTR1A HTR2A
45 serotonin syndrome 28.8 CYP2D6 CYP3A4 HTR1A HTR2A MAOA SLC6A4
46 borderline personality disorder 28.6 BDNF COMT HTR1A HTR2A HTR2C MAOA
47 alcohol dependence 28.6 BDNF CNR1 COMT CRHR1 HTR1A HTR2A
48 mood disorder 28.3 BDNF COMT CRH CRHR1 HTR1A HTR2A
49 major depressive disorder 28.1 BDNF COMT CRH CRHR1 CYP2D6 HTR1A
50 disease of mental health 27.9 BDNF CNR1 COMT CRH CYP2D6 HTR1A

Comorbidity relations with Anxiety via Phenotypic Disease Network (PDN): (show top 50) (show all 80)


Acute Cor Pulmonale Acute Cystitis
Acute Stress Disorder Adjustment Disorder
Allergic Rhinitis Atrophic Gastritis
Atypical Depressive Disorder Basilar Artery Insufficiency
Benign Essential Hypertension Borderline Personality Disorder
Bronchiectasis Bronchitis
Bronchopneumonia Cerebrovascular Disease
Chronic Myocardial Ischemia Chronic Pulmonary Heart Disease
Chronic Rhinitis Conn's Syndrome
Conversion Disorder Deficiency Anemia
Delusional Disorder Dependent Personality Disorder
Dyskinesia of Esophagus Dysthymic Disorder
Esophagitis Familial Atrial Fibrillation
First-Degree Atrioventricular Block Gastroesophageal Reflux
Generalized Anxiety Disorder Generalized Atherosclerosis
Heart Disease Histrionic Personality Disorder
Hyperlipoproteinemia, Type Iv Hypertension, Essential
Hypertensive Encephalopathy Hyperuricemia, Pulmonary Hypertension, Renal Failure, and Alkalosis Syndrome
Hypochondriasis Hypothyroidism
Intermediate Coronary Syndrome Intestinal Obstruction
Iron Deficiency Anemia Irritable Bowel Syndrome
Ischemic Heart Disease Labyrinthitis
Major Depressive Disorder Malignant Essential Hypertension
Meniere Disease Migraine with or Without Aura 1
Mitral Valve Disease Mood Disorder

Graphical network of the top 20 diseases related to Anxiety:



Diseases related to Anxiety

Symptoms & Phenotypes for Anxiety

Clinical features from OMIM:

607834

UMLS symptoms related to Anxiety:


nervousness, agitation, feeling tense, mental and behavioral signs and symptoms, feeling jittery, anxiety symptoms, sleeplessness

MGI Mouse Phenotypes related to Anxiety:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.25 TPH2 BDNF CCKBR CNR1 COMT CRH
2 homeostasis/metabolism MP:0005376 10.13 TPH2 BDNF CCKBR CNR1 COMT CRH
3 cardiovascular system MP:0005385 10.07 CCKBR COMT CRHR1 HTR1A MAOA NR3C1
4 nervous system MP:0003631 9.97 BDNF CCKBR CNR1 COMT CRH CRHR1
5 adipose tissue MP:0005375 9.91 TPH2 CNR1 CRH HTR2C NR3C1 TPH1
6 integument MP:0010771 9.91 BDNF CCKBR CNR1 CRH HTR2C NR3C1
7 no phenotypic analysis MP:0003012 9.5 BDNF CNR1 CRH CRHR1 HTR1A NR3C1
8 respiratory system MP:0005388 9.23 PTK7 TPH1 TPH2 BDNF COMT CRH

Drugs & Therapeutics for Anxiety

Drugs for Anxiety (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 1311)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Alprazolam Approved, Illicit, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable 28981-97-7 2118
2
Valproic Acid Approved, Investigational Phase 4,Phase 2,Phase 3,Not Applicable,Early Phase 1 99-66-1 3121
3
Pregabalin Approved, Illicit, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 148553-50-8 5486971
4
Nitrous oxide Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 10024-97-2 948
5
Dexmedetomidine Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 113775-47-6 68602 5311068
6
Buspirone Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 36505-84-7 2477
7
Paroxetine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 61869-08-7 43815
8
Propofol Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 2078-54-8 4943
9
Midazolam Approved, Illicit Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 59467-70-8 4192
10
Lorazepam Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 846-49-1 3958
11
Benzocaine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 1994-09-7, 94-09-7 2337
12
Etomidate Approved Phase 4,Not Applicable 33125-97-2 36339 667484
13
Remifentanil Approved Phase 4,Phase 2,Phase 3,Not Applicable 132875-61-7 60815
14
Rocuronium Approved Phase 4,Phase 3 119302-91-9, 143558-00-3 441290
15
Sufentanil Approved, Investigational Phase 4,Phase 2,Not Applicable 56030-54-7 41693
16
Tramadol Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable,Early Phase 1 27203-92-5 33741
17
Citalopram Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 59729-33-8 2771
18
Diazepam Approved, Illicit, Investigational, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1,Not Applicable 439-14-5 3016
19
Dronabinol Approved, Illicit Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 1972-08-3 16078
20
Oxytocin Approved, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 50-56-6 439302 53477758
21
Acetylcysteine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 616-91-1 12035
22
Moxonidine Approved, Investigational Phase 4 75438-57-2 4810
23
Drospirenone Approved Phase 4 67392-87-4 68873
24
Estradiol Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 50-28-2 5757
25 Estradiol valerate Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 979-32-8
26
Menthol Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 2216-51-5 16666
27
Polyestradiol phosphate Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 28014-46-2
28
Dopamine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 51-61-6, 62-31-7 681
29
Methylphenidate Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 113-45-1 4158
30
Acetylcholine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 51-84-3 187
31
Lidocaine Approved, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 137-58-6 3676
32
Gabapentin Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable,Early Phase 1 60142-96-3 3446
33
gamma-Aminobutyric acid Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable,Early Phase 1 56-12-2 119
34
Fluvoxamine Approved, Investigational Phase 4,Phase 3,Phase 1,Not Applicable 54739-18-3 3404 5324346
35
Histamine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 75614-87-8, 51-45-6 774
36
Mianserin Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 24219-97-4 4184
37
Mirtazapine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 85650-52-8, 61337-67-5 4205
38
Norepinephrine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 51-41-2 439260
39
Carbamazepine Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 298-46-4 2554
40
Coal tar Approved Phase 4,Phase 2,Not Applicable 8007-45-2
41
Olanzapine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 132539-06-1 4585
42
Oxcarbazepine Approved Phase 4,Phase 3,Not Applicable 28721-07-5 34312
43
Ziprasidone Approved Phase 4,Phase 3,Phase 2,Not Applicable 146939-27-7 60854
44
Medroxyprogesterone acetate Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 71-58-9
45
Progesterone Approved, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 57-83-0 5994
46
Ethanol Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 64-17-5 702
47
Lamotrigine Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 84057-84-1 3878
48
Acamprosate Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 77337-76-9 71158
49
Naltrexone Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable 16590-41-3 5360515
50
Aripiprazole Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 129722-12-9 60795

Interventional clinical trials:

(show top 50) (show all 10140)
# Name Status NCT ID Phase Drugs
1 Drug Treatment Validation of Functional Magnetic Resonance Imaging in Generalized Anxiety Disorder Unknown status NCT00662259 Phase 4 Alprazolam (Xanax);Placebo
2 Quetiapine SR and Divalproex Sodium ER in the Treatment of Anxiety in Bipolar Disorder With Panic Disorder and/or GAD Unknown status NCT00579280 Phase 4 quetiapine SR;divalproex sodium ER;placebo
3 The Effect of Sihogayonggolmoryeo-tang on the Anxiety of Hwa-byung Unknown status NCT01362114 Phase 4 SIHOGAYONGGOLMORYU TANG EXTRACT GRAN
4 Effects of a Probiotic Supplement on Symptoms of Attention Deficit Hyperactivity Disorder and Anxiety in Children Unknown status NCT02545634 Phase 4
5 Perioperative Pregabalin Use, Rehabilitation, Pain Outcomes and Anxiety Following Hip Surgery Unknown status NCT00762099 Phase 4 Pregabalin;Placebo
6 Preoperative Anxiety and Postoperative Pain in Children Unknown status NCT00643032 Phase 4
7 Effect of Music Over the Tolerance to Colonoscopy. Unknown status NCT01285284 Phase 4
8 Impact of 50% Nitrous Oxide Inhalation on Pain and Anxiety Induced by Lumbar Puncture: a Double-blind Randomized Controlled Trial Unknown status NCT02243826 Phase 4 50:50 mixture of nitrous oxide/oxygen
9 A Comparison of Two Doses of Intranasal Dexmedetomidine for Premedication in Children Unknown status NCT02459509 Phase 4 Dexmedetomidine
10 Assessment of the Effectiveness of a Program of Preparation to Pregnancy and Delivery Unknown status NCT01155804 Phase 4
11 Randomized,Controlled and Open-label Study of Buspirone add-on Treatment in Patients With Major Depression Disorder Unknown status NCT02273154 Phase 4 Buspirone;Paroxetine
12 Effect Site Controlled, Reaction Time Safeguarded, Patient Maintained Sedation With Propofol in Anxious Patients Unknown status NCT00355693 Phase 4
13 Oral Midazolam for Sedation in Esophagogastroduodenoscopy(EGD) Unknown status NCT01990937 Phase 4 Oral midazolam
14 Effect of Additive Lorazepam on Patient Satisfaction as a Premedication in Diagnostic Flexible Bronchoscopy Unknown status NCT01121055 Phase 4 Lorazepam;Control
15 Effectiveness of Repetitive Transcranial Magnetic Stimulation in Depressed Patients Unknown status NCT02213016 Phase 4
16 Myoinositol for the Treatment of Ovarian and Psychiatric Disorder in Polycystic Ovary Syndrome (PCOS) Patients Unknown status NCT01246310 Phase 4
17 Clinical Trial to Evaluate the Efficacy of FITOGYN Versus Placebo on the Vasomotor Symptomatology Associated With Menopause Unknown status NCT01116310 Phase 4 Soy isoflavones (Glycine max L) and red clover extract (Trifolium pretense L);Placebo
18 Effects of Dexmedetomidine on Postoperative Cognitive Dysfunction During One-lung Ventilation in Elder Patients Unknown status NCT02134093 Phase 4 Induction of anesthesia,midazolam ,sufentanil,etomidate and rocuronium;Dexmedetomidine;Normal saline;Maintenance of anesthesia , propofol, remifentanil,vecuronium
19 Tramadol Extended-Release (ER) for Posttraumatic Stress Disorder (PTSD) Unknown status NCT01517711 Phase 4 Tramadol;Placebo
20 The CAPTAIN Trial: Cerebrolysin Asian Pacific Trial in Acute Brain Injury and Neurorecovery Unknown status NCT01606111 Phase 4 Cerebrolysin;0.9% NaCl, saline
21 Efficacy Study of Escitalopram for Depression in Patients With Diabetes Unknown status NCT00650897 Phase 4 Escitalopram
22 Eyegaze Systems for Spinal Cord Injury: A Feasibility Study Unknown status NCT01943656 Phase 4
23 DECARD: Study of Escitalopram in the Prevention of Depression in Patients With Acute Coronary Syndrome Unknown status NCT00140257 Phase 4 Escitalopram
24 Customized Acoustic Stimulation for Long Term Medical Benefit for the Relief of Tinnitus and Hyperacusis Unknown status NCT00730834 Phase 4
25 Prevention of Posttraumatic Stress Disorder (PTSD) With Diazepam Unknown status NCT01221883 Phase 4 Diazepam
26 The ED50 of DEX for Providing Sedation in Different Female Age Group Unknown status NCT02773017 Phase 4 Dexmedetomidine A;Dexmedetomidine B;Dexmedetomidine C
27 Clinical Trial to Evaluate the Efficacy and the Tolerance of an Omega 3 Fatty Acids Supplementation in ADHD Children Unknown status NCT00770627 Phase 4
28 Add on Study on Δ9-THC Treatment for Posttraumatic Stress Disorders (PTSD) Unknown status NCT00965809 Phase 4 Tetrahydrocannabinol
29 Impact of Probiotic Preparation VSL#3 on Infants Colics Unknown status NCT01869426 Phase 4
30 Placebo Controlled Evaluation of Sedation and Physiological Response to Intranasal Dexmedetomidine in Severe COPD Unknown status NCT02773797 Phase 4 IN-DEX 1.0 mcg/kg, intranasal saline;IN-DEX 1.5 mcg/kg, intranasal saline;Placebo - Saline
31 The Effect of 21-Days Intranasal Oxytocin on Patients With Post Traumatic Stress Disorder (PTSD) Unknown status NCT02336568 Phase 4 Oxytoine;PLACEBO
32 The Use of Oral N-Acetyl Cysteine for the Treatment of Chronic Sinonasal Symptoms Unknown status NCT00866866 Phase 4 N-Acetyl Cysteine;Placebo
33 Study of the Effect of Moxonidine and Diet on Sympathetic Functions in Young Adults With Obesity Unknown status NCT01180231 Phase 4 Moxonidine (Physiotens)
34 Climacteric Clinical Trial : the Use of Complementary Therapy and Hormonal Replacement Unknown status NCT00617500 Phase 4 Hormones
35 Methylphenidate in Healthy Young Adults Unknown status NCT00815841 Phase 4 METHYLPHENIDATE
36 Study of the Safety and Efficacy of Botox in Bruxism Unknown status NCT00908050 Phase 4 Botulinum toxin type A
37 Ultrasound Guided Cannulation of Dialysis Fistulas Unknown status NCT01163981 Phase 4
38 Paracervical Block for Pain Control in First Trimester Abortion Unknown status NCT01094366 Phase 4
39 Creative Therapy to Affect Stroke Outcomes Unknown status NCT01455155 Phase 4
40 Effect of Gabapentin on Pain of the Second Cataract Surgery Unknown status NCT02127853 Phase 4 gabapentin;placebo
41 Costs of Lost Productive Time Among Korean Workers With Panic Disorder and Effect of Treatment With Paroxetine Controlled Release Unknown status NCT00492414 Phase 4 Paroxetine CR
42 Cost-Effectiveness of Adding Web-Based Cognitive-Behavioral Therapy (CBT) to Luvox CR for Obsessive Compulsive Disorder (OCD) Unknown status NCT00743834 Phase 4 Luvox CR
43 Postoperative Recovery in Elderly Patients Undergoing Hip Hemi-arthroplasty Unknown status NCT01934049 Phase 4 Total Intravenous Anesthesia and Peripheral nerve blocks
44 Tolerability And Efficacy Of High Dose Escitalopram In The Treatment Of Patients Suffering From Schizophrenia And Obsessive-Compulsive Disorder (OCD) - An Open Label Study Unknown status NCT00708396 Phase 4 Escitalopram
45 Hippocampal Volume in Young Patients With Major Depression Before and After Combined Antidepressive Therapy Unknown status NCT00150839 Phase 4 Mirtazapine;Venlafaxine
46 Comparative Efficacy and Acceptability of Antimanic Drugs in Acute Mania Unknown status NCT01893229 Phase 4 Lithium;Valproate;Oxcarbazepine;Quetiapine;Olanzapine;Ziprasidone
47 Multi-centre Clinical Trial on Hormone Replacement Treatment in China Unknown status NCT01698164 Phase 4 estradiol plus MPA;Ximingting Tablet;estradiol plus progesterone
48 Therapeutic Effects of Video Game Play Therapy on Patients With Chronic Low Back Pain Unknown status NCT02125968 Phase 4
49 Management of Chronic Pain in Military Patients With Injuries Sustained During Active Duty Unknown status NCT01616342 Phase 4
50 Transcranial Magnetic Stimulation for Post-Traumatic Stress Disorder Unknown status NCT00134446 Phase 4

Search NIH Clinical Center for Anxiety

Inferred drug relations via UMLS 73 / NDF-RT 51 :


Cochrane evidence based reviews: anxiety disorders

Genetic Tests for Anxiety

Genetic tests related to Anxiety:

# Genetic test Affiliating Genes
1 Anxiety 29 SLC6A4

Anatomical Context for Anxiety

MalaCards organs/tissues related to Anxiety:

41
Brain, Breast, Testes, Heart, Lung, Prostate, Skin

Publications for Anxiety

Articles related to Anxiety:

(show top 50) (show all 6242)
# Title Authors Year
1
Could we use parent report as a valid proxy of child report on anxiety, depression, and distress? A systematic investigation of father-mother-child triads in children successfully treated for leukemia. ( 29049860 )
2018
2
Sex differences in the neuro-immune consequences of stress: Focus on depression and anxiety. ( 28216088 )
2018
3
Developmental trajectories of math anxiety during adolescence: Associations with STEM career choice. ( 29975882 )
2018
4
How deep is our anxiety during treatment of thyroid cancer? ( 29972434 )
2018
5
Interaction between the Opioid Receptor OPRM1 Gene and Mother-Child Language Style Matching Prospectively Predicts Children's Separation Anxiety Disorder Symptoms. ( 29576267 )
2018
6
Mobile and traditional cognitive behavioral therapy programs for generalized anxiety disorder: A cost-effectiveness analysis. ( 29300754 )
2018
7
Efficacy of vortioxetine in working patients with generalized anxiety disorder- ERRATUM. ( 29880074 )
2018
8
Reappraising Preclinical Models of Separation Anxiety Disorder, Panic Disorder, and CO<sub>2</sub> Sensitivity: Implications for Methodology and Translation into New Treatments. ( 29696603 )
2018
9
Behavioral Inhibition Underlies the Link Between Interoceptive Sensitivity and Anxiety-Related Temperamental Traits. ( 29977219 )
2018
10
How do anxiety affect CD34 and CD3 cells in allogeneic peripheral blood stem cell transplantation? ( 29439917 )
2018
11
Neural activity to threat in ventromedial prefrontal cortex correlates with individual differences in anxiety and reward processing. ( 29981291 )
2018
12
Desacyl Ghrelin Decreases Anxiety-like Behavior in Male Mice. ( 29155981 )
2018
13
History of mood or anxiety disorders and risk of gestational diabetes mellitus in a population-based cohort. ( 29120506 )
2018
14
Hands train the brain-what is the role of hand tremor and anxiety in undergraduate microsurgical skills? ( 29968093 )
2018
15
The effect of panic disorder versus anxiety sensitivity on event-related potentials during anticipation of threat. ( 29291580 )
2018
16
Anxiety and Depression: A Cross-sectional Survey among Parents of Children with Cancer. ( 29440813 )
2018
17
Compromised dynamic cerebral autoregulation in patients with generalized anxiety disorder: a study using transfer function analysis. ( 29859053 )
2018
18
The aldehyde dehydrogenase 2 polymorphisms on neuropsychological performance in bipolar II disorder with or without comorbid anxiety disorder. ( 29425204 )
2018
19
COPD in Primary Care: Key Considerations for Optimized Management: Anxiety and Depression in Chronic Obstructive Pulmonary Disease: Recognition and Management. ( 29443332 )
2018
20
Heart-focused anxiety and health care seeking in patients with non-cardiac chest pain: A prospective study. ( 29120733 )
2018
21
Underestimated caregiver burden by cancer patients and its association with quality of life, depression and anxiety among caregivers. ( 29333736 )
2018
22
Predicting the Effectiveness of Work-Focused CBT for Common Mental Disorders: The Influence of Baseline Self-Efficacy, Depression and Anxiety. ( 29450678 )
2018
23
Relationships Among Avoidant Personality Disorder, Social Anxiety Disorder, and Normative Personality Traits: A Twin Study. ( 29505386 )
2018
24
Association of Depression and Anxiety Disorders With Autoimmune Thyroiditis: A Systematic Review and Meta-analysis. ( 29800939 )
2018
25
Predicting Social Anxiety From Global Positioning System Traces of College Students: Feasibility Study. ( 29973337 )
2018
26
Attachment Avoidance and Anxiety in Adolescence: Turkish Adaptation of the Experiences in Close Relationships-Relationship Structures Scale. ( 29979103 )
2018
27
Treating a Child With Anxiety and Attention-Deficit/Hyperactivity Disorder? Don't Rule Out Cognitive-Behavioral Therapy. ( 29960689 )
2018
28
A Review of Evidence Based Treatments for Transgender Youth Diagnosed with Social Anxiety Disorder. ( 29445772 )
2018
29
Psychoactive substance abuse and dependence and its association with anxiety disorders: a population-based study of young adults in Brazil. ( 29451585 )
2018
30
Innovations in the psychosocial treatment of youth with anxiety disorders: implications for a stepped care approach. ( 29976564 )
2018
31
Anxiety-Related Behaviours Associated with microRNA-206-3p and BDNF Expression in Pregnant Female Mice Following Psychological Social Stress. ( 28092086 )
2018
32
MGCD0103, a selective histone deacetylase inhibitor, coameliorates oligomeric AI^<sub>25-35</sub> -induced anxiety and cognitive deficits in a mouse model. ( 29978554 )
2018
33
Impact of generalized anxiety disorder (GAD) on prehospital delay of acute myocardial infarction patients. Findings from the multicenter MEDEA study. ( 29383439 )
2018
34
Identification of Distinct Latent Classes Related to Sleep, PTSD, Depression, and Anxiety in Individuals Diagnosed With Severe Alcohol Use Disorder. ( 29377714 )
2018
35
Kava for Generalized Anxiety Disorder: A Review of Current Evidence. ( 29641222 )
2018
36
Risk Factors, Clinical Presentations, and Functional Impairments for Generalized Anxiety Disorder in Military Personnel and the General Population in Canada. ( 29304289 )
2018
37
Comparing the efficacy of benzodiazepines and serotonergic anti-depressants for adults with generalized anxiety disorder: a meta-analytic review. ( 29806492 )
2018
38
Administration of Allium cepa L. bulb attenuates stress-produced anxiety and depression and improves memory in male mice. ( 29178012 )
2018
39
Toll-like receptor-4 regulates anxiety-like behavior and DARPP-32 phosphorylation. ( 29221855 )
2018
40
The effect of multimedia-based nursing visit on preoperative anxiety and vital signs in patients undergoing lumbar disc herniation surgery: A randomised clinical trial. ( 29376786 )
2018
41
A neural biomarker, the error-related negativity, predicts the first onset of generalized anxiety disorder in a large sample of adolescent females. ( 29665048 )
2018
42
Extending knowledge of illegitimate tasks: Student satisfaction, anxiety, and emotional exhaustion. ( 28681395 )
2018
43
Psychoeducation against depression, anxiety, alexithymia and fibromyalgia: a pilot study in primary care for patients on sick leave. ( 29693478 )
2018
44
When Did Coloring Books Become Mindful? Exploring the Effectiveness of a Novel Method of Mindfulness-Guided Instructions for Coloring Books to Increase Mindfulness and Decrease Anxiety. ( 29441038 )
2018
45
Bilingualism, a human right in times of anxiety: Lessons from California. ( 29124953 )
2018
46
Executive Attention and Empathy-Related Responses in Boys with Oppositional Defiant Disorder or Conduct Disorder, With and Without Comorbid Anxiety Disorder. ( 29752662 )
2018
47
Alpha-Linolenic Acid Treatment Reduces the Contusion and Prevents the Development of Anxiety-Like Behavior Induced by a Mild Traumatic Brain Injury in Rats. ( 28844093 )
2018
48
Psychiatrists' treatment preferences for generalized anxiety disorder. ( 29266492 )
2018
49
Alexithymia and autistic traits as possible predictors for traits related to depression, anxiety, and stress: A multivariate statistical approach. ( 29882629 )
2018
50
Is there an association between maternal anxiety propensity and pregnancy outcomes? ( 29973180 )
2018

Variations for Anxiety

ClinVar genetic disease variations for Anxiety:

6
# Gene Variation Type Significance SNP ID Assembly Location
1 46;XY;t(6;12)(q14;q24);20p+dn complex Pathogenic
2 46;XX;t(2;11)(q11.2;p13)dn Translocation Pathogenic
3 46;XY;t(2;6)(q33;q21)dn Translocation Pathogenic
4 46;XY;t(1;2)(p34.2;q35)dn Translocation Pathogenic
5 HMBS NM_000190.3(HMBS): c.958delG (p.Ala320Leufs) deletion Likely pathogenic rs1057518806 GRCh37 Chromosome 11, 118963865: 118963865
6 HMBS NM_000190.3(HMBS): c.958delG (p.Ala320Leufs) deletion Likely pathogenic rs1057518806 GRCh38 Chromosome 11, 119093155: 119093155
7 OTX2 NM_172337.2(OTX2): c.167_169delTGTinsGG (p.Leu56Argfs) indel Likely pathogenic GRCh38 Chromosome 14, 56804268: 56804270
8 OTX2 NM_172337.2(OTX2): c.167_169delTGTinsGG (p.Leu56Argfs) indel Likely pathogenic GRCh37 Chromosome 14, 57270986: 57270988

Copy number variations for Anxiety from CNVD:

7
# CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 139649 2 185171337 185512459 Deletion ZNF804A anxiety disorder

Expression for Anxiety

Search GEO for disease gene expression data for Anxiety.

Pathways for Anxiety

Pathways related to Anxiety according to GeneCards Suite gene sharing:

(show all 20)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.35 CCKBR CNR1 CRH CRHR1 HTR1A HTR2A
2
Show member pathways
12.88 BDNF CNR1 CRH CRHR1 HTR2A HTR2C
3 12.41 CNR1 COMT HTR1A TPH1 TPH2
4
Show member pathways
12.04 CYP3A4 MAOA TPH1 TPH2
6 11.97 BDNF HTR1A HTR2A MAOA NR3C1 SLC6A4
7
Show member pathways
11.82 HTR1A HTR2A HTR2C
8 11.76 CCKBR CNR1 HTR2A
9 11.61 CYP2D6 HTR1A HTR2A HTR2C MAOA SLC6A4
10
Show member pathways
11.46 COMT CYP2D6 CYP3A4 SLC6A4
11
Show member pathways
11.43 COMT CYP2D6 CYP3A4
12
Show member pathways
11.27 MAOA SLC6A4 TPH2
13
Show member pathways
11 COMT MAOA SLC6A4
14 10.89 HTR2A HTR2C
15
Show member pathways
10.89 COMT MAOA TPH1
16
Show member pathways
10.74 COMT MAOA
17 10.7 COMT MAOA
18 10.66 CCKBR CNR1
19 10.61 HTR1A HTR2A HTR2C MAOA SLC6A4 TPH1
20 10.37 CRH CRHR1

GO Terms for Anxiety

Cellular components related to Anxiety according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes